A Phase I, First in Human, Dose-Escalation Study of UCT-03-008 in Participants withAdvanced Solid Tumors
NCT #
NCT05103046
Condition(s)
Lung Cancer (NSCLC), Renal Cell Cancer, Solid Tumor
Molecular Target(s)
CDK4/6
Drug Classification(s)
Small Molecule, Targeted Therapy
Agents(s)
UCT-03-008
Phase(s)
I
Mechanism of Action
UCT-03-008, CDK4/6 inhibitor, inhibits protein kinase from working and therefore, potentially stopping cancer cells to grow. Protein kinases are enzymes that are involved in the signaling pathway of cells that tell some cells to grow or to stop growing in the body.
Purpose
- How much of the study drug can be given alone with an acceptable level of side effects
- The effects of the study drug (good and bad) when given alone
- How much of the study drug is absorbed into the blood and how fast it is removed when given alone
Location
MCD
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.